dedicator of cytokinesis 6Genealiases: AOS2 · ZIR1
Q-omics provides the consensus-scored DOCK6 profile across patient tissues and cancer cell-line models. DOCK6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, DOCK6 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, DOCK6 RNA expression shows 19,155 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KIRC, and THYM as cancer lineages where DOCK6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for DOCK6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes DOCK6 survival associations across molecular data types. DOCK6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (9) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible DOCK6 RNA expression–survival associations across cancer types. High DOCK6 expression shows unfavorable associations in MESO, KIRP and LGG, but favorable associations in HNSC, KIRC and UCEC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for DOCK6 RNA expression.
This table summarizes DOCK6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for DOCK6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. DOCK6 shows lower tumor expression in LUAD and higher tumor expression in KIRC, HNSC, COAD, LIHC and STAD. The KIRC box plot shows higher DOCK6 RNA expression in tumor versus normal tissue (log2 FC = +1.323, t-test p < 0.001).
This table shows molecular features associated with DOCK6 in patient tissues and cancer cell lines. In patient samples, DOCK6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, DOCK6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
